Ukwandisa inzuzo yophuhliso lwanamhlanje olulungileyo lwempilo yabemi ngogunyaziso lwe-Food and Drug Administration's (FDA) lwe-antiviral yomlomo yokuqala yonyango lwe-COVID-19 kwimarike, i-EMed ilungiselela ukuhlangabezana naloo mfuno. Inkampani iyayincoma i-FDA kunye nePfizer ngeli nyathelo libalulekileyo kumlo ochasene ne-COVID-19.
Uvavanyo lokuNyanga™, ulwandiso kwisisombululo sayo sangoku sasekhaya, esiqinisekisiweyo sovavanyo, senzelwe ukuququzelela ubonelelo olukhawulezileyo lonyango lonyango lwe-antiviral kubathengi bayo ukuba banokuvavanywa bene-COVID-19. Unyango olutsha oluvunyiweyo lwe-antiviral olusuka kwi-Pfizer lusebenza kakhulu xa luqalwe ngokukhawuleza emva kokuxilongwa kwe-COVID-19 kwaye kwisithuba seentsuku ezintlanu kuqale kweempawu - iqonga liyilelwe ukuvala umsantsa phakathi kokuxilongwa kunye nonyango ukusuka kwintuthuzelo kunye nokhuseleko lonyango. ikhaya labathengi. Ngeedola ezingama-25 zeedola, umthengi unokutyelela iwebhusayithi yenkampani ukuba ikhokelwe kwinkqubo yokuvavanya ekhaya kwaye afumane iziphumo eziqinisekisiweyo kwimizuzu eyi-15 enokukhokelela kummiselo we-antiviral yomlomo ukuba ihlangabezana nemigaqo efunekayo.
Inkampani ikwalungele ukuxhasa ubonelelo lukarhulumente lovavanyo lwasimahla ngokunikezela ngeziphumo eziqinisekisiweyo. Oku kuthetha ukuba abantu baseMelika banokufumana uvavanyo lwasimahla kurhulumente kwaye basebenzise i-eMed ukufumana iziphumo eziqinisekisiweyo ezifunekayo kuhambo, umsebenzi kunye nokunye.
